


Neurizon Therapeutics:

A new horizon in neurodegenerative disease treatment



Science-led. Patient-driven. Globally connected.

Neurizon Therapeutics is an Australian clinical-stage biotechnology company advancing next-generation treatments for neurodegenerative diseases such as **Amyotrophic Lateral Sclerosis (ALS)** – also known as **Motor Neurone Disease (MND)** – **Huntington’s Disease (HD)** and other neurodegenerative diseases.

Our mission is simple yet meaningful: *To bring forward next-generation treatments that make a real difference in the lives of people affected by neurodegenerative diseases and their loved ones.* We are building more than a biotech company – we are creating a community united by science, compassion, and purpose.

Our Lead ALS Investigational Therapy: NUZ-001

NUZ-001 is an investigational, **orally administered therapy** designed to **address the root causes of ALS**, not just its symptoms.

It works by supporting the brain's natural ability to clear misfolded proteins and restore cellular balance — mechanisms disrupted in ALS and related conditions.

By targeting **TDP-43 protein aggregation**, seen in more than 95% of ALS patients, NUZ-001 aims to protect neurons and slow disease progression.

Our Progress So Far

Phase 1 and Open-Label Extension (OLE) Study Results in small population in Australia

- **Safety and Tolerability:** Long-term treatment with NUZ-001 was safe and well-tolerated. No treatment-related serious adverse events were reported.
- **Encouraging Clinical Signals:** Topline results demonstrated early signs of benefit across survival, functional decline, respiratory outcomes, and biomarkers.
- **Long-term Benefit:** Participants who continued in the OLE study maintained safety and demonstrated consistent trends supporting NUZ-001's therapeutic potential.

These results provide a strong foundation for the **next stage — the Phase 2/3 HEALEY ALS Platform Trial** led by researchers at the **Healey & AMG Center for ALS at Massachusetts General Hospital** and the **Network for Excellence in ALS (NEALS)**, one of the world's **most advanced ALS research networks**. The preparation for the trial are on schedule and the trial is expected to commence in Q1 2026.

Looking Ahead

We are entering a pivotal phase of development as NUZ-001 moves toward **global clinical evaluation** and eventual **patient access** through the HEALEY ALS Platform Trial in the United States.

With Orphan Drug Designation (U.S. FDA and EMA) and a global license agreement with Elanco, Neurizon is strategically positioned to advance NUZ-001 efficiently and responsibly.

While early or expanded access is not yet available outside of the completed OLE study, a small number of former participants in Australia continue to receive NUZ-001 under the TGA's Special Access Scheme.

The next opportunity for patients to access NUZ-001 will be through the planned Phase 2/3 HEALEY ALS Platform Trial in the United States. We are working urgently to expand access through future trials so that more people living with ALS may benefit.

Our Commitment to the ALS Community

Neurizon is deeply committed to patient-centric research – designing studies with the input of people living with ALS, their families, clinicians, and advocacy groups.

By partnering with leading patient associations and research networks across Australia, the U.S., and Europe, we aim to ensure that every step we take reflects what matters most: improving lives and advancing hope.

Together we can create hope by delivering meaningful progress for people living with ALS.

